Regulatory Effect of Iguratimod on the Balance of Th Subsets and Inhibition of Inflammatory Cytokines in Patients with Rheumatoid Arthritis

Table 2

Experimental assessment of RA patients undergoing iguratimod treatment.

	Group A			Group B
	0 w	24 w	52 w	0 w	24 w	52 w
ESR (mm/h)	40.48 ± 19.7	20.21 ± 12.84	28.14 ± 19.09	38.29 ± 16.89	37.63 ± 31.22	27.59 ± 27.96
CRP (mg/L)	17.98 ± 16.35	10.18 ± 13.93	17.17 ± 18.83	22.40 ± 22.93	24.38 ± 27.84	12.65 ± 18.66
RF (IU/mL)	357.79 ± 540.61	221.83 ± 461.93	248.74 ± 463.33	215.71 ± 229.22	330.92 ± 373.91	162.70 ± 254.67
IgG (g/L)	17.10 ± 4.55	14.24 ± 3.11	14.13 ± 2.93	16.11 ± 3.63	15.81 ± 3.99	14.07 ± 3.80
IgM (g/L)	1.98 ± 1.67	1.46 ± 0.99	1.51 ± 0.92	1.75 ± 0.88	1.71 ± 0.73	1.66 ± 1.35
IgA (g/L)	3.47 ± 1.11	2.82 ± 1.16	2.89 ± 1.22	2.87 ± 1.17	3.17 ± 1.68	2.17 ± 1.13

ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; RF: rheumatoid factor.